Welichem Biotech Inc. (TSX-V: WBI) has entered into an exclusive agreement with Stiefel, a GSK company, pursuant to which Stiefel has agreed to acquire the exclusive development and commercialization rights to Welichem...
To Read This Article, Please Login or Subscribe
For $5 plus HST a month (recurring), you will have access to all our premium contents (database access is not included). For database subscription, please click here.
